These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 19028704)
1. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Rebbeck TR; DeMichele A; Tran TV; Panossian S; Bunin GR; Troxel AB; Strom BL Carcinogenesis; 2009 Feb; 30(2):269-74. PubMed ID: 19028704 [TBL] [Abstract][Full Text] [Related]
2. Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States. Slattery ML; Baumgartner KB; Giuliano AR; Byers T; Herrick JS; Wolff RK Breast Cancer Res Treat; 2011 Sep; 129(2):531-9. PubMed ID: 21475998 [TBL] [Abstract][Full Text] [Related]
3. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Shan J; Mahfoudh W; Dsouza SP; Hassen E; Bouaouina N; Abdelhak S; Benhadjayed A; Memmi H; Mathew RA; Aigha II; Gabbouj S; Remadi Y; Chouchane L Breast Cancer Res Treat; 2012 Oct; 135(3):715-24. PubMed ID: 22910930 [TBL] [Abstract][Full Text] [Related]
4. Genetic variants in FGFR2 and TNRC9 genes are associated with breast cancer risk in Pakistani women. Mazhar A; Jamil F; Bashir Q; Ahmad MS; Masood M; Tanvir I; Rashid N; Waheed A; Afzal MN; Tariq MA Mol Med Rep; 2016 Oct; 14(4):3443-51. PubMed ID: 27572905 [TBL] [Abstract][Full Text] [Related]
5. Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. Jara L; Gonzalez-Hormazabal P; Cerceño K; Di Capua GA; Reyes JM; Blanco R; Bravo T; Peralta O; Gomez F; Waugh E; Margarit S; Ibañez G; Romero C; Pakomio J; Roizen G Breast Cancer Res Treat; 2013 Jan; 137(2):559-69. PubMed ID: 23225170 [TBL] [Abstract][Full Text] [Related]
6. Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer. Özgöz A; İçduygu FM; Yükseltürk A; ŞamlI H; Öztürk KH; Başkan Z J Genet; 2020; 99():. PubMed ID: 32366738 [TBL] [Abstract][Full Text] [Related]
7. Association of polymorphisms in intron 2 of FGFR2 and breast cancer risk in Сhinese women. Pan Z; Bao Y; Zheng X; Cao W; Cheng W; Xu X Tsitol Genet; 2016; 50(5):59-64. PubMed ID: 30480917 [TBL] [Abstract][Full Text] [Related]
8. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Liang J; Chen P; Hu Z; Zhou X; Chen L; Li M; Wang Y; Tang J; Wang H; Shen H Carcinogenesis; 2008 Dec; 29(12):2341-6. PubMed ID: 18845558 [TBL] [Abstract][Full Text] [Related]
9. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Barnholtz-Sloan JS; Shetty PB; Guan X; Nyante SJ; Luo J; Brennan DJ; Millikan RC Carcinogenesis; 2010 Aug; 31(8):1417-23. PubMed ID: 20554749 [TBL] [Abstract][Full Text] [Related]
10. Variants of estrogen-related genes and breast cancer risk in European and African American women. Quan L; Hong CC; Zirpoli G; Roberts MR; Khoury T; Sucheston-Campbell LE; Bovbjerg DH; Jandorf L; Pawlish K; Ciupak G; Davis W; Bandera EV; Ambrosone CB; Yao S Endocr Relat Cancer; 2014; 21(6):853-64. PubMed ID: 25228414 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. Garcia-Closas M; Hall P; Nevanlinna H; Pooley K; Morrison J; Richesson DA; Bojesen SE; Nordestgaard BG; Axelsson CK; Arias JI; Milne RL; Ribas G; González-Neira A; Benítez J; Zamora P; Brauch H; Justenhoven C; Hamann U; Ko YD; Bruening T; Haas S; Dörk T; Schürmann P; Hillemanns P; Bogdanova N; Bremer M; Karstens JH; Fagerholm R; Aaltonen K; Aittomäki K; von Smitten K; Blomqvist C; Mannermaa A; Uusitupa M; Eskelinen M; Tengström M; Kosma VM; Kataja V; Chenevix-Trench G; Spurdle AB; Beesley J; Chen X; ; ; Devilee P; van Asperen CJ; Jacobi CE; Tollenaar RA; Huijts PE; Klijn JG; Chang-Claude J; Kropp S; Slanger T; Flesch-Janys D; Mutschelknauss E; Salazar R; Wang-Gohrke S; Couch F; Goode EL; Olson JE; Vachon C; Fredericksen ZS; Giles GG; Baglietto L; Severi G; Hopper JL; English DR; Southey MC; Haiman CA; Henderson BE; Kolonel LN; Le Marchand L; Stram DO; Hunter DJ; Hankinson SE; Cox DG; Tamimi R; Kraft P; Sherman ME; Chanock SJ; Lissowska J; Brinton LA; Peplonska B; Klijn JG; Hooning MJ; Meijers-Heijboer H; Collee JM; van den Ouweland A; Uitterlinden AG; Liu J; Lin LY; Yuqing L; Humphreys K; Czene K; Cox A; Balasubramanian SP; Cross SS; Reed MW; Blows F; Driver K; Dunning A; Tyrer J; Ponder BA; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gabrieau V; Sigurdson A; Doody M; Struewing JP; Alexander B; Easton DF; Pharoah PD PLoS Genet; 2008 Apr; 4(4):e1000054. PubMed ID: 18437204 [TBL] [Abstract][Full Text] [Related]
12. Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility. Dankova Z; Zubor P; Grendar M; Kapinova A; Zelinova K; Jagelkova M; Gondova A; Dokus K; Kalman M; Lasabova Z; Danko J Gen Physiol Biophys; 2017 Dec; 36(5):565-572. PubMed ID: 29372690 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. Andersen SW; Trentham-Dietz A; Figueroa JD; Titus LJ; Cai Q; Long J; Hampton JM; Egan KM; Newcomb PA Menopause; 2013 Mar; 20(3):354-8. PubMed ID: 23435034 [TBL] [Abstract][Full Text] [Related]
14. GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients. Cox DG; Curtit E; Romieu G; Fumoleau P; Rios M; Bonnefoi H; Bachelot T; Soulié P; Jouannaud C; Bourgeois H; Petit T; Tennevet I; Assouline D; Mathieu MC; Jacquin JP; Lavau-Denes S; Darut-Jouve A; Ferrero JM; Tarpin C; Lévy C; Delecroix V; Trillet-Lenoir V; Cojocarasu O; Meunier J; Pierga JY; Faure-Mercier C; Blanché H; Sahbatou M; Boland A; Bacq D; Besse C; Deleuze JF; Pauporté I; Thomas G; Pivot X Oncotarget; 2016 Nov; 7(47):77358-77364. PubMed ID: 27764800 [TBL] [Abstract][Full Text] [Related]
15. MYC amplification in subtypes of breast cancers in African American women. Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126 [TBL] [Abstract][Full Text] [Related]
16. Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Huijts PE; Vreeswijk MP; Kroeze-Jansema KH; Jacobi CE; Seynaeve C; Krol-Warmerdam EM; Wijers-Koster PM; Blom JC; Pooley KA; Klijn JG; Tollenaar RA; Devilee P; van Asperen CJ Breast Cancer Res; 2007; 9(6):R78. PubMed ID: 17997823 [TBL] [Abstract][Full Text] [Related]
17. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Cen YL; Qi ML; Li HG; Su Y; Chen LJ; Lin Y; Chen WQ; Xie XM; Tang LY; Ren ZF Mol Carcinog; 2013 Nov; 52 Suppl 1():E52-9. PubMed ID: 23143756 [TBL] [Abstract][Full Text] [Related]
18. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Travis RC; Reeves GK; Green J; Bull D; Tipper SJ; Baker K; Beral V; Peto R; Bell J; Zelenika D; Lathrop M; Lancet; 2010 Jun; 375(9732):2143-51. PubMed ID: 20605201 [TBL] [Abstract][Full Text] [Related]
19. Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women. Gorodnova TV; Kuligina ESh; Yanus GA; Katanugina AS; Abysheva SN; Togo AV; Imyanitov EN Cancer Genet Cytogenet; 2010 May; 199(1):69-72. PubMed ID: 20417875 [No Abstract] [Full Text] [Related]
20. Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk. Wang H; Yang Z; Zhang H Breast Cancer Res Treat; 2013 Jan; 137(2):511-22. PubMed ID: 23184080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]